(proparacaine HCI ophthalmic solution) 0.5%
OPHTHETIC® (proparacaine HCI ophthalmic solution) 0.5% is a topical local anesthetic for ophthalmic use.
OPHTHETIC® ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g., tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.
Media Articles Related to Ophthetic (Proparacaine Ophthalmic)
Combining dental, medical procedures may safely limit children's anesthesia exposure
Source: Dentistry News From Medical News Today [2016.10.27]
Children who require both dental and non-dental medical procedures should have them completed under one general anesthesia session whenever possible, which is ideal for both the patient and family...
Trends in Tramadol: Pharmacology, Metabolism, and Misuse
Source: Medscape Anesthesiology Headlines [2017.02.15]
Learn about the unique characteristics of tramadol, its pharmacogenomic considerations, and its potential for abuse in this comprehensive review.
Anesthesia & Analgesia
UW study: Incidence of consciousness during surgery lower than previous estimates
Source: Pain / Anesthetics News From Medical News Today [2016.12.19]
An international study of 260 surgical patients found that, contrary to many previous studies, just more than four percent were conscious of the external world while under general anesthesia but...
Published Studies Related to Ophthetic (Proparacaine Ophthalmic)
Dilute proparacaine for the management of acute corneal injuries in the emergency department. [2010.09]
OBJECTIVE: Dogma discourages the provision of topical anesthetics to patients with corneal injuries discharged from the emergency department because of the toxicity of concentrated solutions. We compared the analgesic efficacy of dilute topical proparacaine with placebo in emergency department patients with acute corneal injuries... CONCLUSION: Dilute topical proparacaine is an efficacious analgesic for acute corneal injuries. Although no adverse events were observed in our study population, larger studies are required to evaluate safety.
Subtenon lidocaine vs topical proparacaine in adult strabismus surgery. [2006.09]
Intraoperative subtenon 2% lidocaine and topical 0.5% proparacaine in patients undergoing strabismus surgery were compared. No additional systemic analgesics and sedatives were used.Topical 0.5% proparacaine may be preferred because of its easy administration and fewer side effects, lack of hospital admission, and immediate and predictable alignment of the eyes.
Duration of effect and effect of multiple doses of topical ophthalmic 0.5% proparacaine hydrochloride in clinically normal dogs. [2005.01]
OBJECTIVE: To determine the duration of effect and the effect of multiple doses of topical ophthalmic application of 0.5% proparacaine hydrochloride on corneal sensitivity in clinically normal dogs...
A randomised comparison of lidocaine 2% gel and proparacaine 0.5% eye drops in
paediatric squint surgery. 
We conducted a randomised trial comparing lidocaine 2% gel with proparacaine 0.5%
eye drops in children having elective squint surgery. One hundred and forty
children aged between 3 and 14 years were recruited... We conclude that, compared with proparacaine 0.5% eye drops,
a single application of lidocaine 2% gel improves peri-operative analgesia and
reduces the incidence of postoperative nausea and vomiting in elective paediatric
Effect of a proparacaine 0.50%-sodium fluorescein 0.25% mix and contact ultrasound pachymetry on central and midperipheral corneal thickness measured by noncontact optical pachymetry. [2011.05]
PURPOSE: To assess the effect of a combination of proparacaine 0.50%-sodium fluorescein 0.25% and ultrasound (US) pachymetry on central and midperipheral corneal thickness. SETTING: School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales, United Kingdom... CONCLUSIONS: Ultrasound pachymetry combined with proparacaine 0.50%-sodium fluorescein 0.25% caused a small (<10 mum) but significant amount of corneal swelling on average. Because the effect on corneal thickness may be greater than -10 to +30 mum in individual cases, clinicians should avoid contact procedures before obtaining topographic maps of corneal thickness using scanning-slit and Scheimpflug devices. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Ophthetic (Proparacaine Ophthalmic)
Proparacaine and Mydriatic Eye Drops [Terminated]
In this study, we will be evaluating whether premedication with an anesthetic eye drops
leads to a decreased sensation of pain when given dilating eye drops prior to eye
examinations to evaluate for retinopathy of prematurity in neonatal intensive care unit
Proparacaine vs Placebo for Corneal Injuries [Completed]
Introduction: Traumatic injuries to the outer covering of the eye (the cornea) are a common
emergency department complaint. They cause significant patient distress including pain,
loss of sleep and missed work days. There is currently no accepted, uniform approach to
pain management in this patient population. Emergency medicine and ophthalmology texts
state that prolonged use of medications that anesthetize the cornea is not recommended.
Several recent publications in the ophthalmology literature show that the outpatient use of
dilute local anesthesia in patients after eye surgery is a safe and effective method of pain
control. In this study, we used Proparacaine (a local anesthetic), in a similar manner, for
the outpatient emergency department management of traumatic corneal injuries.
Methods: We performed a clinical trial on a sample of adult patients presenting with
traumatic corneal injuries to two university affiliated emergency departments in London,
Patients providing signed informed consent to participate in the study received a vial of
clear liquid that contained either Proparacaine or plain water (placebo), a pain log,
topical antibiotics and oral Acetaminophen (Tylenol) with Codeine for breakthrough pain.
Patients were instructed to use the "study drug" on an "as-needed" basis for the next seven
days. Patients completed a pain scale describing their discomfort immediately prior to, and
five minutes after self-administration of the study drug. All patients were followed closely
in an ophthalmology outpatient clinic on Days 1, 3 and 5 after presentation to the emergency
department. At the last ophthalmology clinic visit, the patients' pain logs were collected.
The protocol was approved by the Research Ethics Board for Health Sciences Research
Involving Human Subjects at the University of Western Ontario.
Comparison of Three Different Anesthetic Approaches for Intravitreal Injections [Completed]
92 patients in treatment with intravitreal injections were randomized to 1 of 3 groups:
proparacaine 0. 5% drops (Group Drops), proparacaine 0. 5% drops plus subconjunctival
lidocaine (Group SC), or 2% lidocaine gel (Group Gel). Patients were asked to score their
pain experience using a visual analogue scale (VAS), a scale of 0 to 10, immediately
following the injections as well as 10 minutes, 1 hour, 6 hours and 24 hours after. Patients
also graded the overall injection experience as Excellent, Very Good, Fair, Poor or Awful.
The physician evaluated the patient's eye movement during intravitreal injection in three
levels: none or minimal (0), not compromising the injection (1), compromising the injection
Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections [Completed]
There are currently several different commercially available topical eye drops and gels used
to reduce eye discomfort (topical anesthetics) during and after eye injections. Dr. Pollack
is performing a research study to evaluate three commercially available topical anesthetics
(eye numbing treatments) to determine if individuals have a preference for one over the
other. The three topical anesthetics being studied are 1) 0. 5% proparacaine hydrochloride
(generic, Akorn, Inc), 2) 0. 5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%
lidocaine hydrochloride topical solution (generic, Roxane Laboratories), and 3) 3. 5%
lidocaine hydrochloride ophthalmic gel (Akten, Akorn, Inc). These eye anesthetics are NOT
experimental medications. They are all commercially available topical anesthetics currently
used in our offices and their use is widespread among retina specialists throughout the
United States. Dr. Pollack will randomly select one topical anesthetic to use and he will
ask you to grade your level of pain associated with the injection procedure. Answering these
questions should take less than one minute of your time and your identity will NOT be
revealed with the results of this study. The results of this study will be used to inform
doctors which eye anesthetics patients find most effective for pain control during eye
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection [Active, not recruiting]
This study is designed to compare four currently used types of anesthesia used for
intravitreal injection in order to evaluate the most effective method of anesthesia in
reducing pain and discomfort associated with intravitreal injections.
Page last updated: 2017-02-15